Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer

On November 7, 2011, the U.S. Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Approval was based on a randomized stud...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Cohen, Martin H., Chen, Huanyu, Shord, Stacy, Fuchs, Chana, He, Kun, Zhao, Hong, Sickafuse, Sharon, Keegan, Patricia, Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2013
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639534/
https://ncbi.nlm.nih.gov/pubmed/23576486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0458
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados